PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from 16 studies highlighting the role of Guardant blood tests and real-world data in advancing precision oncology and cancer screening at the 2024 American Society for Clinical Oncology (ASCO) Annual Meeting, May 31-June 4 in Chicago.
Featured presentations will share data supporting the utility of therapy response monitoring with circulating tumor DNA (ctDNA) using Guardant Infinity and the use of the GuardantINFORM™ clinical-genomic database to characterize drivers and resistance mechanisms and their association with real-world outcomes in a variety of solid tumor types. Additional studies will present data supporting the application of genomic and epigenomic biomarkers in areas such as minimal residual disease detection and cohort characterization.
“The robust data we present at ASCO will further demonstrate the important scientific and clinical developments in cancer care that are possible using liquid biopsy,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “Several studies will highlight the tremendous potential of epigenomic analysis using our Guardant Infinity platform to quantify tumor fraction and characterize therapy resistance mechanisms in order to improve treatment response across multiple cancer types.”
Featured presentations include:
- An oral presentation of a study using the Guardant360® liquid biopsy and exploring racial differences in genomic profiles and targeted treatment use in ER+ HER2- metastatic breast cancer (Abstract 1017, Monday, June 3, 11:30 am – 1:00 pm, Hall D1)
- Interim data readout from the collaboration between Guardant Health and the Parker Institute for Cancer Immunotherapy (PICI) to identify genomic and epigenomic biomarkers using Guardant Infinity for quantification of tumor fraction and association with outcomes from the RADIOHEAD real-world advanced pan-cancer cohort (Abstract 2570, Saturday, June 1, 9:00 am – 12:00 pm, Hall A)
Complete list of Guardant Health and collaborator presentations at ASCO
Abstract |
Title (Hall A unless otherwise noted) |
Product |
Saturday, June 1 | 9:00 am – 12:00 pm
2570 |
Use of a tissue-free epigenomic circulating tumor DNA (ctDNA) assay for quantification of tumor fraction (TF) and association with outcomes from RADIOHEAD real-world advanced pan-cancer cohort |
Guardant Infinity |
||
3041 |
Association of KRAS G12D vs. G12V circulating tumor DNA variant allele fraction and real-world overall survival in metastatic non-small cell lung and colorectal cancers |
Guardant Infinity |
Saturday, June 1 | 1:30 pm – 4:30 pm
LBA3557 |
A randomized study evaluating tailoring of advanced/metastatic colorectal cancer (mCRC) therapy using circulating tumor DNA (ctDNA): TACT-D |
Guardant360 CDx |
||
3519 |
Candidate molecular alterations associated with potential resistance in KRAS G12D gastrointestinal cancers |
Guardant360 & Guardant360/CDx |
||
3602 |
Characteristics of patients (pts) with disease relapse despite absence of molecular residual disease (MRD) after resection of colorectal oligometastases (CRM): implications from PRECISION study |
Guardant360 & Guardant Reveal™ |
||
3545 |
Characterization of mutational signatures demonstrating adaptive mutability post anti-EGFR therapy in a real-world metastatic colorectal cancer cohort |
GuardantINFORM |
Sunday, June 2 | 9:00 am – 12:00 pm
1037 |
Molecular profiling of serial liquid biopsy specimens utilizing cell free DNA (cfDNA) and circulating tumor cells (CTCs) in TBCRC041: A phase II study of alisertib in endocrine resistant metastatic breast cancer (MBC) |
Guardant Infinity |
||
1043 |
Evaluating metrics of circulating tumor DNA response and progression using a high sensitivity tumor-agnostic assay in metastatic HR+/HER2- breast cancer receiving endocrine therapy and a CDK4/6-inhibitor |
Guardant Infinity |
||
1071 |
Real-world (RW) elacestrant use patterns and therapeutic outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC) |
GuardantINFORM |
||
5069 |
Dynamic androgen receptor alterations (ARa) ctDNA profiles and clinical outcomes in metastatic prostate cancer (mPC) |
GuardantINFORM |
Monday, June 3 | 9:00 am – 12:00 pm | Hall A
5592 |
Serial circulating tumor DNA (ctDNA) sequencing to monitor response and define acquired resistance to letrozole/abemaciclib in endometrial cancer (EC) |
Guardant Infinity |
Monday, June 3 | 11:30 am – 1:00 pm | Hall D1
1017 |
Rapid Oral Abstract Session: Racial differences in genomic profiles and targeted treatment use in ER+ HER2- metastatic breast cancer |
Guardant360 |
Online only
e13097 |
Co-occurrence of ESR1 and PIK3CA mutations in HR+/HER2- metastatic breast cancer: Incidence and outcomes with targeted therapy |
Guardant360 & Guardant360 CDx |
||
e12566 |
Molecular profiling in ABC: Is complementary testing with tissue and plasma necessary and clinically relevant? |
Guardant360 |
||
e13702 |
Utilization of circulating tumor DNA (ctDNA) testing by race and ethnicity in more than 135,000 patients |
GuardantINFORM |
||
e20088 |
Use of cell-free tumor DNA in early detection of lung cancer |
Shield™ (next generation) |
The full abstracts for Guardant Health and a list of all abstracts being presented at the meeting can be found at the ASCO website.
For more information and updates from the meeting, follow Guardant Health on LinkedIn and X (Twitter) or visit ASCO booth #28115.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2023, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
